…peaked feels premature. The loud TikTok-style hype may have cooled, but the interest is just getting redistributed into more niche compounds and longevity circles. Same circus, slightly less confetti.
Like most biotech cycles, peptide hype feels past its peak now that novelty has worn off. The conversation seems a bit more grounded than it was a year or two ago.
The signal-to-noise ratio definitely feels better now that the novelty cycle is cooling off—less “this peptide fixes everything,” more attention on which mechanisms actually hold up.
Are you sure it peaked, or has the hype just shifted from broad “peptides” to a few specific compounds and longevity claims? What makes you think we’re past the peak—less discussion, less funding, or people moving on to the next trend?
Discussion 34